A more stable prognostic risk assessment model was established using self-service internal validation methods, including seven GPRs (CPXM1, CD48, GPR132, PRF1, CTSW, TBC1D10C, and PLEKHO2) combined with five protective immune cells (CD8 T cells, activated NK cells, monocytes, resting mast cells, and M1 macrophages), to evaluate the prognosis of patients with STS. This evidence concerns the gene GPR132 and telomere syndrome.